Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Travera Inc
Eastern Cooperative Oncology Group
Washington University School of Medicine
Vanderbilt-Ingram Cancer Center
Eastern Cooperative Oncology Group
Mayo Clinic
MacroGenics
Washington University School of Medicine
National Cancer Institute (NCI)